NVCR - Zai Lab's margetuximab meets primary endpoint in phase 2 breast cancer study

Margetuximab, a monoclonal antibody for HER2+ breast cancer under development from Zai Lab (NASDAQ:ZLAB), met its primary endpoint in a phase 2 study in previously treated patients in China. The primary endpoint was median progression-free survival. The hazard ratio for progression-free survival in the study favored a combination of margetuximab + chemo compared to Herceptin (trastuzumab) + chemo, achieving the primary endpoint. Zai Lab is planning to submit a BLA in China for margetuximab by the end of the year. Yesterday, Zai Lab and Novocure (NASDAQ:NVCR) announced they finished enrollment in a phase 2 gastric adenocarcinoma study evaluating Tumor Treating Fields.

For further details see:

Zai Lab's margetuximab meets primary endpoint in phase 2 breast cancer study